Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05884697 · ClinicalTrials.gov registry record · NA
Let's K-Talk - HPV Study for Ethnic Koreans
A NA study of Papillomavirus Vaccines and Human Papillomavirus Viruses, sponsored by University of Cincinnati.
- Active
- Registry status
- NA
- Development phase
- 120
- Enrollment target
- 1
- Study location
NCT05884697: Active NA study of Papillomavirus Vaccines and Human Papillomavirus Viruses, sponsored by University of Cincinnati.
NCT05884697 is a NA study of Papillomavirus Vaccines and Human Papillomavirus Viruses that is active but no longer recruiting, run by University of Cincinnati. The registered enrollment target is 120 participants, below the 3,882-participant average among 4 other Papillomavirus Vaccines trials with a reported enrollment target (97% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05884697, a NA study of Papillomavirus Vaccines and Human Papillomavirus Viruses, is active but no longer recruiting, sponsored by University of Cincinnati.
- ACTIVE NOT RECRUITING
- Registry status
- NA
- Development phase
- 120 participants
- Enrollment target
- 1
- Study location
Study Summary
The goal of this clinical trial is to test the feasibility, acceptability, and preliminary efficacy of a storytelling video-based intervention using AI chatbot technology (K-Talk) to promote HPV vaccination behavior among Korean Americans aged 18 to 45. The main questions this study aims to answer are: * Is the K-Talk intervention feasible for use among Korean Americans aged 18 to 45? * Is the K-Talk intervention acceptable to the target population? * What is the preliminary efficacy of the K-Talk intervention in promoting HPV vaccination uptake? Participants will be Korean Americans aged 18 to 45 who are at risk for HPV infection. Participants will be asked to complete a baseline survey and then will be "randomized" into one of four groups: Group 1 (chatbot + storytelling intervention), Group 2 (chatbot only), Group 3 (storytelling only), and Group 4 will be only exposed to written didactic HPV education materials. All groups will receive written didactic HPV education materials. Researchers will compare how Group 1, a combination of AI Chatbot and storytelling intervention is more effective than other intervention groups in promoting HPV vaccination uptake among underserved, hard-to-reach Korean Americans.
Primary Outcome
Completion of 3 doses of HPV vaccines
Conditions Studied
Interventions
- OTHER K-Talk Intervention (Storytelling and K-Bot)
- OTHER Storytelling Intervention
- OTHER K-Bot Intervention
- OTHER Written Information
Study Locations (1)
Ohio
- Minjin Kim - Cincinnati
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 120 participants |
| Start Date | 2023-05-10 |
| Est. Completion | 2026-07-31 |
| Phase | NA |
What the registry record for NCT05884697 still lists
NCT05884697 is an interventional study that assigns participants to a tested intervention. The registered 120 participants enrollment target is mid-sized for trials with a published cap, below the 3,882-participant average among 4 other Papillomavirus Vaccines trials with a reported enrollment target (97% lower).
The record links to 2 conditions, with Papillomavirus Vaccines appearing as the primary indexed condition, and to 4 interventions - of which K-Talk Intervention (Storytelling and K-Bot) is the first listed.
NCT05884697 reports a single indexed study location in Ohio.
Frequently Asked Questions
What is clinical trial NCT05884697 about?
NCT05884697 is a clinical study titled "Let's K-Talk - HPV Study for Ethnic Koreans". The goal of this clinical trial is to test the feasibility, acceptability, and preliminary efficacy of a storytelling video-based intervention using AI chatbot technology (K-Talk) to promote HPV vaccination behavior among Korean Americans aged 18 to 45. The main questions this study aims to answer ...
What is the current status of trial NCT05884697?
This trial is currently active not recruiting. It is a NA study. The enrollment target is 120 participants. The study started on 2023-05-10. Estimated completion is 2026-07-31.
What conditions does trial NCT05884697 study?
This clinical trial studies the following conditions: Papillomavirus Vaccines, Human Papillomavirus Viruses.
What interventions are being tested in trial NCT05884697?
The interventions under investigation include: K-Talk Intervention (Storytelling and K-Bot) (OTHER), Storytelling Intervention (OTHER), K-Bot Intervention (OTHER), Written Information (OTHER).
Who is sponsoring clinical trial NCT05884697?
This trial is sponsored by University of Cincinnati, which has 245 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05884697 being conducted?
This trial has 1 study location across Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Papillomavirus Vaccines
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
ReMARK: Addressing Disparities in Rural HPV-related Cancer Prevention
RECRUITING · NA
-
Impact of Adolescent Vaccine Reminder Notices Sent Via Preferred Method of Communication on HPV Vaccination
ACTIVE NOT RECRUITING · NA
-
Provider-Focused Intervention for Maximizing HPV Vaccine Uptake in Young Cancer Survivors
ACTIVE NOT RECRUITING · NA
-
Immunogenicity of Gardasil-9 HPV Vaccine in People Living With HIV
RECRUITING · Phase 4
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01174108 · 120 participants · Phase 2
Allogeneic Hematopoietic Stem Cell Transplantation for Severe Aplastic Anemia and Other Bone Marrow Failure Syndromes Using G-CSF Mobilized CD34+ Selected Hematopoietic Precursor Cells Co-Infused With a Reduced Dose of Non-Mobilized Donor T-cells
- NCT01627301 · 120 participants · NA
Sympathetic Overactivity in Post-traumatic Stress Disorder
- NCT02025023 · 120 participants · Phase 3
Local 5-Fluorouracil Injection for the Treatment of Chalazia: A Prospective, Comparative Study
- NCT02128906 · 120 participants · Phase 2
Radiotherapy With Cisplatin vs. Docetaxel-cetuximab in HNSCC: ERCC1 Biomarker Enrichment and Interaction Design
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI